8-K: Vaxart Adjourns Annual Stockholders Meeting to June 2, Continues to Solicit Votes

Vaxart has adjourned its 2025 annual meeting of stockholders to June 2, 2025, to allow stockholders additional time to vote on key proposals, including a potential reverse stock split.

Summary

• Vaxart adjourned its 2025 annual meeting of stockholders on May 21, 2025.
• The meeting has been rescheduled for June 2, 2025, at 8:30 a.m. Pacific Time and will be held virtually.
• The adjournment aims to provide stockholders with more time to vote on the proposals outlined in the proxy statement filed on April 10, 2025.
• The company will continue to solicit votes during the adjournment period.
• Stockholders who have already voted do not need to recast their votes unless they wish to change them.
• The record date for determining stockholders eligible to vote remains March 26, 2025.
• One key proposal is a reverse stock split, which the board believes is in the best interest of stockholders to regain Nasdaq compliance and attract investors.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the adjournment itself isn't inherently positive or negative, the focus on a reverse stock split to maintain Nasdaq compliance suggests underlying concerns about the stock price. The company's proactive approach to soliciting votes is a positive sign.

Positives

• The company is proactively ensuring all stockholders have ample opportunity to vote.
• The board believes the reverse stock split is beneficial for maintaining the Nasdaq listing and attracting investors.

Risks

• The company acknowledges risks and uncertainties that could cause actual results to differ materially from anticipated results, including continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Companys most recent Annual Report on Form 10-K and other filings with the SEC.

Future Outlook

The company will continue to solicit votes and proceed with the reconvened annual meeting on June 2, 2025.

Management Comments

• The Board of Directors of Vaxart believes that the approval of Proposal No. 2 regarding the Reverse Stock Split is in the best interests of the stockholders of Vaxart.

Industry Context

Biotech companies often face challenges in maintaining Nasdaq listing compliance, and reverse stock splits are a common strategy to address this issue. Vaxart's focus on oral recombinant vaccines positions it within a competitive landscape of companies developing novel vaccine delivery methods.

Comparison to Industry Standards

• Many biotechnology companies facing similar stock price challenges have implemented reverse stock splits to maintain exchange listing requirements.
• Comparable companies that have undertaken reverse stock splits include [hypothetical company A] and [hypothetical company B], which experienced [hypothetical result A] and [hypothetical result B] respectively following their reverse splits.
• Vaxart's rationale for the reverse stock split aligns with industry best practices for companies seeking to improve investor perception and attract institutional investment.

Stakeholder Impact

• Shareholders are directly impacted by the adjournment and the potential reverse stock split.
• Employees may be indirectly affected by the company's efforts to maintain its Nasdaq listing, which can influence investor confidence and the company's ability to attract and retain talent.

Next Steps

• Vaxart will continue to solicit votes from stockholders.
• The reconvened Annual Meeting will be held on June 2, 2025.
• Stockholders are encouraged to vote by June 1, 2025.

Key Dates

Keywords

annual meeting, stockholders, adjournment, reverse stock split, proxy vote, Vaxart, VXRT